Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 14/20 | 1.00 |
| ▸ | PARP1 | P09874 | 2/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.51 |
| ▸ | CTSV | O60911 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136730 | 0.94 | KIF11 (0.89) | KIF11PARP1GABRA1GABRG2GABRB3 | |
| SCHEMBL4132327 | 0.93 | KIF11 (0.86) | KIF11PARP1GABRA1GABRG2GABRB3 | |
| SCHEMBL29540314 | 0.81 | GABRA1 (0.70) | KIF11PARP1GABRA1GABRG2GABRB3 | |
| SCHEMBL155013 | 0.81 | GABRA1 (0.70) | KIF11PARP1GABRA1GABRG2GABRB3 | |
| SCHEMBL6008297 | 0.78 | PARP1 (0.73) | KIF11PARP1GABRA1GABRG2GABRB3 | |
| SCHEMBL29993384 | 0.78 | PARP1 (0.73) | KIF11PARP1GABRA1GABRG2GABRB3 | |
| SCHEMBL19785406 | 0.78 | KIF11 (0.81) | KIF11CA12CA9 | |
| SCHEMBL151534 | 0.77 | CTSV (0.79) | KIF11PARP1GABRA1GABRG2GABRB3 | |
| SCHEMBL30272742 | 0.77 | CTSV (0.79) | KIF11PARP1GABRA1GABRG2GABRB3 | |
| SCHEMBL30272743 | 0.77 | CTSV (0.79) | KIF11PARP1GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170882-A1 | Methods and compositions | CYTOKINETICS, INCORPORATED | 2009-07-02 | — | — | US | disclosed |
| US-20090170882-A1 | Methods and compositions | CYTOKINETICS, INCORPORATED | 2009-07-02 | — | — | US | disclosed |
| EP-1771176-A2 | METHODS AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006005063-A2 | METHODS AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170882-A1 | Methods and compositions | KIF5B, KIF5C, KIF2C | KIF11 10/4885PARP1 1291/4885GABRA1 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.